---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059333"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:03:52.614197+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow

## Summary
- Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.
- Net loss $67.6M ($0.56/share) vs $136.9M ($1.23/share) YoY; achieved ~$3M positive cash flow.
- Processed ~735,800 tests (+17.5%); oncology tests ~114,800 (+61.7%).
- Launched fetal RhD NIPT test; published key data in oncology and organ health.
- FY 2024 guidance: revenue $1.42B-$1.45B; gross margin 53-55%; net cash ($25M)-$25M.

## SEC filing metadata
- accession: 0001104659-24-059333
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465924059333/0001104659-24-059333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465924059333/tm2413904d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059333
- JSON: https://secwatch.observer/filing/0001104659-24-059333.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059333.txt

## Key facts
- Earnings Releases
  Natera, Inc. reported first quarter ended March 31, 2024 results: revenue $367.7 million, net income net loss of $67.6 million, EPS ($0.56) per diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $367.7 million
  - Net income: net loss of $67.6 million
  - EPS: ($0.56) per diluted share
  - Result: reported results
  source text: First Quarter Ended March 31, 2024 Financial Results Total revenues were $367.7 million in the first quarter of 2024 compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. The increase in total revenues was driven primarily by a 53.4% increase in product revenues, which were $364.7 million in the first quarter of 2024 compared to $237.8 million in the first quarter of 2023. The increase in product revenues was primarily driven by an increase in volume, as well as average selling price improvements. Natera processed approximately 735,800 tests in the first quarter of 2024, including approximately 718,700 tests accessioned in its laboratory, compared to approximately 626,200 tests processed, including approximately 607,700 tests accessioned in its laboratory, in the first quarter of 2023. In the first quarter of 2024, Natera recognized revenue on approximately 679,400 tests for which results were reported to customers in the period (tests reported), including appr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604821/000110465924059333/0001104659-24-059333-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.